Conformis Names Dan Krupp Senior Vice President U.S. Sales
BILLERICA, Mass., July 11, 2017 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants customized to fit each patient’s unique anatomy, today announced that Dan Krupp has joined the Company as its Senior Vice President of U.S. Sales, effective July 3, 2017.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/75f70387-ab76-48cd-bf98-27c3569e87df.
“The addition of Dan to our leadership team is another example of our commitment to developing additional expertise and support that will help us execute our commercial strategy,” said Mark Augusti, Chief Executive Officer and President of Conformis. “We are very excited to have Dan join us. His extensive experience in leading top-ranked sales organizations in startup, turnaround, volatile, and growth markets will be a tremendous asset for Conformis.”
Mr. Krupp has more than 20 years of sales and marketing experience in medical devices and total joint arthroplasty. From 2002-2014, he held positions of increasing responsibility at DePuy Synthes, developing and executing sales strategies and managing multiple new product launches. Most recently, he was Vice President, Sales and Marketing, at JACE Medical, where he successfully managed the development and execution of a range of corporate and product branding initiatives.
“I am very pleased to be joining the outstanding team at Conformis and to play a role in reshaping the future of arthroplasty with the company’s disruptive technology platform,” said Mr. Krupp. “I look forward to leading the U.S. sales force during what we believe will be a transformative period in orthopedics.”
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses approximately 450 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.
Cautionary Statement Regarding Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Conformis, including statements about Conformis’s commercial strategy, future results, and orthopedic and arthroplasty markets, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our clinical studies and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Conformis’s views as of the date hereof. Conformis anticipates that subsequent events and developments may cause Conformis’s views to change. However, while Conformis may elect to update these forward-looking statements at some point in the future, Conformis specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Conformis’s views as of any date subsequent to the date hereof.
The photo is also available via AP PhotoExpress.
Investor Contact: Oksana Bradley email@example.com (781) 374-5598 Media Contact: Bill Berry Berry & Company Public Relations Bberry@berrypr.com (212) 253-8881
Conformis Achieves 100,000 Implant Milestone for Patient-Specific Knee Replacement Technology
Conformis’ Patient-Specific Knee Implant Technology Is Complemented by New 3D-designed Hip System Launched in November 2019 BILLERICA, Mass., Jan. 30,
Conformis Announces FDA Clearance and Full Commercial Launch of Next Generation Hip System at the 2019 AAHKS Conference
Designed to enhance operational efficiency for the surgeon, the Conformis Hip System is the most advanced, patient-conforming hip replacement system